CNTX-4975 appears to have failed its P3 clinical trials, like most of PAR's other so called competitors. Reality is there are no other major competitors yet, but Novartis is probably the biggest threat. Who knows, maybe Novartis may look to acquire PAR in the future if their candidate also fails trials.
https://endpts.com/exclusive-centrexions-knee-pain-drug-fails-two-phiii-studies-but-ex-pfizer-ceo-kindlers-biotech-might-still-ask-for-fda-nod/
CNTX-4975 appears to have failed its P3 clinical trials, like...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $101.4M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.5¢ | $79.93K | 274.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12951 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 23984 | 3 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |